• Envoy Medical held its annual shareholder meeting on May 12, 2026.
• Shareholders authorized an increase of 6,000,000 shares available for issuance under the 2023 Equity Incentive Plan, with the amendment taking effect upon approval.
• Investors also authorized an additional 1,200,000 shares for issuance under the 2023 Employee Stock Purchase Plan, effective upon approval.
• Shareholders ratified EisnerAmper as independent registered public accounting firm for the year ending Dec. 31, 2026.
• Investors approved the issuance of warrants and the Class A common stock underlying those warrants tied to a transaction completed on Feb. 12, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Envoy Medical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-058429), on May 18, 2026, and is solely responsible for the information contained therein.